Cancer
Seprase (FAP) is emerging as a viable target for cancer therapy, given its biological roles within tumor microenvironments. At Alfa Cytology, with our best-in-class platforms and commitment to seprase (FAP)-targeted therapeutics and diagnostics in multiple cancers, we aim to provide a comprehensive solution to that end.
Introduction to Seprase (FAP)-Targeted Therapeutics for Cancer
Seprase (FAP) is a member of the family of type II transmembrane serine proteases, a serine protease with two enzymatic functions. Seprase (FAP) is commonly overexpressed in a variety of epithelial tumors, particularly in tumor-associated fibroblasts. Seprase (FAP) is an important protein in the development, maturation, and function of most tumors: its enzymatic activity promotes tumor cell invasion into the stroma. It has thus become an interesting target for the diagnosis and treatment of cancer. Nowadays, notable therapeutic options include FAP-inhibitory drugs, FAP-activating precursor drugs, seprase (FAP) vaccines, seprase (FAP) antibodies, and CAR-T cell immunotherapy.
Fig. 1 Targeting FAPα-positive lymph node metastatic tumor cells suppresses colorectal cancer metastasis. (Fan, S., et al. 2024)
Seprase (FAP)-Targeted Drug Development for Diverse Cancers
The following are drugs development that target seprase (FAP), including but not limited to:
| Name | Indication | Phase | NCT Number |
|---|---|---|---|
| 68Ga-FAP-2286 | Solid Tumors | Phase I | NCT05180162 |
| 68Ga-FAPI-RGD PET/CT | Lung cancer | Phase I | NCT05543954 |
| 68Ga-FAPI-46 | Prostate Cancer | Phase I | NCT04457232 |
| 68Ga-FAPI-46 | Sarcoma | Phase I | NCT04457258 |
| 68Ga-FAPI-46 | Breast Cancer; Colon Cancer; Esophageal Cancer; Gastric Cancer; Lung Cancer; Neck Squamous Cell Carcinoma; Ovarian Cancer; Pancreatic Cancer; Renal Cancer | Phase I | NCT04147494 |
| 68Ga-FAPI-46 | Pancreatic Cancer | Phase II | NCT05262855 |
| 68F-FAPI-74 | Colon Cancer Cholangiocarcinoma Gastric Cancer Hepatocellular Carcinoma Pancreatic Cancer |
Phase II | NCT05641896 |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Research and advancements in science have made seprase (FAP) therapy the accepted gold standard of cancer therapy. Drug development professionals at Alfa Cytology, supported by a dedicated team of specialists, work tirelessly on research and the provision of seprase (FAP)-targeted therapeutic interventions and diagnostics development against a wide variety of cancers.
Diverse Cancer Types
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
One-Stop Solutions
Alfa Cytology has undertaken the development of targeted drugs against FAP. We are a company that aspires to provide one-stop solutions in drug development directed toward specific cancers. Please contact us for further information on our services and price structure.
Reference
- Fan, S., et al. Targeting FAPα-positive lymph node metastatic tumor cells suppresses colorectal cancer metastasis. Acta pharmaceutica Sinica. 2024, 14(2): 682-697.
For research use only.